Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization

Ninette Cohen, Ilya Novikov, Izhar Hardan, Arif Esa, Frida Brok-Simoni, Ninette Amariglio, Gideon Rechavi, Isaac Ben-Bassat, Luba Trakhtenbrot

Research output: Contribution to journalArticlepeer-review

Abstract

Fluorescence in situ hybridization (FISH), as a new clinical test, is not presently standardized. For practical reasons, each laboratory must build its own criteria. In this work, we present our standardization criteria for clinical practice, which include not only the methods for cell fixation, specimen preparation, and hybridization conditions, but mainly the definition of false-positive range and the scoring criteria of microscopic analysis. These include signal assessment, difference between individual microscopists, evaluation of specimen homogeneity, and the minimum number of scored nuclei required for a clinically reliable result. For this purpose, we analyzed by FISH 24 healthy volunteer donors, 31 patients affected by non-chronic myelogenous leukemia (CML) hematological malignancies, 47 CML patients at diagnosis, and 82 CML patients during treatment for the BCR/ABL fusion. In this article, we present several quality control and assurance methods that can be useful in providing standardization of the FISH technique.

Original languageEnglish
Pages (from-to)102-108
Number of pages7
JournalCancer Genetics and Cytogenetics
Volume123
Issue number2
DOIs
StatePublished - 2000

Fingerprint

Dive into the research topics of 'Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization'. Together they form a unique fingerprint.

Cite this